Brief: Spruce Biosciences Presents Phase 2 POWER Study Results Of Tildacerfont For Treatment Of Polycystic Ovary Syndrome
03/06/2024 14:33
June 3 (Reuters) - Spruce Biosciences Inc SPRB.O :
* SPRUCE BIOSCIENCES PRESENTED PHASE 2 POWER STUDY RESULTS
OF
TILDACERFONT FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME AT
ENDO 2024
Source text for Eikon: ID:nBwzV4hpa
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium